EXODOTS for diagnostic evaluation and monitoring of Alzheimer's disease

EXODOTS 用于阿尔茨海默病的诊断评估和监测

• 批准号: 10600890
• 负责人: Yuchao Chen
• 金额: $ 29.17万
• 依托单位: WELLSIM BIOMEDICAL TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10600890
• 关键词: Alzheimer disease detection; Alzheimer disease screening; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease diagnostic; Alzheimer' s disease model; Alzheimer' s disease patient; Alzheimer’s disease biomarker; Biological Assay; Biological Markers; Biomedical Technology; Blood; Blood - brain barrier anatomy; Blood Circulation; Blood Proteins; Blood Tests; Brain; Brain Injuries; Cerebrospinal Fluid; Clinical; Collection; Cross Reactions; Data; Data Analyses; Detection; Development; Diagnostic; Diagnostic Procedure; Disease; Disease Progression; Early Diagnosis; Evaluation; Goals; Hour; Immunofluorescence Immunologic; Measurement; Measures; Mediator of activation protein; Membrane Proteins; Methods; Monitor; Neurodegenerative Disorders; Neurons; Neuropsychological Tests; Noise; Non-Invasive Cancer Detection; Outcome; Outpatients; Pathogenesis; Peripheral; Phase; Plasma; Plasma Proteins; Procedures; Proteins; Psyche structure; Reporting; Sampling; Sensitivity and Specificity; Severity of illness; Signal Transduction; Small Business Innovation Research Grant; Source; Specificity; Speed; Statistical Data Interpretation; Technology; Testing; Update; base; biomarker panel; circulating biomarkers; clinical diagnosis; cohort; cost; cost effective; design; detection assay; detection limit; detection sensitivity; diagnosis evaluation; diagnostic tool; disease diagnosis; extracellular vesicles; improved; innovation; liquid biopsy; minimally invasive; multiplex detection; neuroimaging; noninvasive diagnosis; novel; primary care setting; screening; tau Proteins; technological innovation

PROJECT SUMMARY / ABSTRACT Alzheimer's disease (AD) is the most widespread neurodegenerative disorder. Despite the severity of the disease, early diagnosis of AD is still challenging due to the low accuracy or high cost of neuropsychological tests and neuroimaging. Development of an accurate and cost-effective technology for non-invasive screening and monitoring of AD before irreversible brain damage or mental decline is critical. WellSIM proposes to develop and validate a highly sensitive immunofluorescence assay, termed EXODOTS, for detection and quantification of AD core biomarkers from circulating extracellular vesicles (EV) with high accuracy, high speed, and low cost. This blood-based assay will facilitate minimally invasive assessment of AD patients in primary care settings and continuous monitoring of disease progression.

项目摘要/摘要 阿尔茨海默病(AD)是最普遍的神经退行性疾病。尽管这种疾病很严重， AD的早期诊断仍然具有挑战性，因为神经心理测试的准确性较低或成本较高 神经成像。开发一种准确且经济高效的非侵入性筛查和治疗技术 在不可逆转的脑损伤或精神衰退之前监测阿尔茨海默病至关重要。WellSIM建议开发和 验证一种称为EXODOTS的高灵敏免疫荧光分析方法，用于AD的检测和定量 从循环细胞外小泡(EV)中提取核心生物标志物具有高精度、高速度和低成本的特点。这 血液化验将有助于在初级保健环境中对AD患者进行微创评估 持续监测疾病进展。